Hereditary predisposition to cancer associated with CTNNA1 is mainly due to heterozygous germline truncating variants that cause loss of function of alpha-E-catenin. It is inherited in an autosomal dominant manner, with incomplete penetrance, and primarily increases the risk of diffuse gastric cancer and, probably to a lesser extent, breast lobular carcinoma. Alteration of cell adhesion favors infiltrative tumor growth.
Hereditary cancer (CTNNA1 gene)
The CTNNA1 gene encodes alpha-E-catenin, an adherens junction protein. It associates with the E-cadherin/beta-catenin complex and connects it to the actin cytoskeleton, helping to maintain the cohesion, polarity, and architecture of epithelia. It also participates in mechanical signals that regulate proliferation when cells contact each other.
Truncating variants can lead to transcripts degraded by RNA surveillance and reduce functional alpha-E-catenin. Subsequent inactivation of the healthy copy in some cells favors the poorly cohesive growth characteristic of diffuse gastric cancer with signet ring cells. The relationship between CTNNA1 and this syndrome is considered definitive, although its penetrance is moderate and lower than that of CDH1. Initial estimates placed the cumulative risk near 49-57% by age 80, but they were obtained from few families and likely overestimated it. Larger studies confirm an increased risk, the absolute magnitude of which is still being defined. A predominant founder variant on a global scale has not been described.
Symptoms
Carrier individuals remain asymptomatic as long as they do not develop cancer. CTNNA1-associated diffuse gastric cancer is frequently diagnosed around age 40, although onset is highly variable. Initial foci can be microscopic and difficult to detect by endoscopy. disease can cause early satiety, weight loss, abdominal pain, nausea, vomiting, dysphagia, anemia, or gastrointestinal bleeding. Lobular breast carcinoma can cause thickening, nipple retraction, or subtle changes without forming a distinct nodule. Many carrier individuals never develop a tumor.
Disease management
There is no treatment that eliminates genetic predisposition. Management requires genetic counseling, directed study of family members, and evaluation in expert units. Gastric surveillance is performed through prolonged endoscopies with directed biopsies and multiple random biopsies, usually every 6-12 months from adulthood or 5-10 years before the earliest family diagnosis. Its sensitivity is limited because foci can be hidden under normal mucosa. Risk-reducing total gastrectomy may be considered for truncating variants with relevant family history or when signet ring cells are detected, but it is not automatically indicated in all carriers; its nutritional and functional consequences require a multidisciplinary decision. In women with personal or family history of breast cancer, intensive surveillance may be recommended, generally with magnetic resonance imaging starting around age 30 and mammography adapted to risk. Established tumors are treated according to their location and stage.
Genes analyzed
Bibliography
Barbosa-Matos R, Córdova L, Schrader K, et al. Diffuse Gastric and Lobular Breast Cancer Syndrome. GeneReviews®. Updated October 10, 2024.
Lobo S, Dias A, Pedro AM, et al. Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier families and over 37,000 non-carrier controls. Gut. 2026;75(5):872-885.
Blair VR, McLeod M, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020;21(8):e386-e397.
Coudert M, Drouet Y, Delhomelle H, et al. First estimates of diffuse gastric cancer risks for carriers of CTNNA1 germline pathogenic variants. J Med Genet. 2022;59(12):1189-1195.
